Advertisement
Skip to Content

Alimera Sciences Inc ALIM Stock Quote

| Rating as of

NASDAQ: ALIM

Last close prices updated as of Feb 06, 2023, 3:59 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 2.7
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Small Value
  • Day Range 2.67  –  2.99
  • Year Range 2.03  –  7.92
  • Market Cap 18.9229 Mil
  • Volume / Avg 9,397.0 /  16,550.4
  • Price / Sales 0.35
  • Price / Book 103.10
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ALIM

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ALIM

Company Profile ALIM

Business Description

Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.

Contact
6310 Town Square, Suite 400
Alpharetta, GA, 30005
Industry Drug Manufacturers - Specialty & Generic
Employees 154

FAQs for Alimera Sciences Inc Stock

No. ALIM does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ALIM’s market cap is 18.92 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ALIM’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ALIM’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ALIM’s historical performance against its industry peers and the overall market.